

APPENDIX 4D HALF YEAR REPORT

Tyrian Diagnostics Limited
ACN 080 277 998

Current Reporting Period	Half Year ended 31 December 2014
Previous corresponding period	Half Year ended 31 December 2013

Results for announcement to the market				\$'000
Revenue from continuing activities	Decreased	91 %	to	28
Revenue and other income from continuing activities	Decreased	91 %	to	28
Loss from continuing activities after tax attributable to members	Increased	249 %	to	163
Loss for the period attributable to members	Increased	249 %	to	163

Dividends/distributions	Amount per security	Franked amount per security
Final dividend	Nil	Nil
Interim dividend	Nil	Nil

Record date for determining entitlements to the interim dividend	N/A
--	-----

NTA Backing

	31 December 2014	31 December 2013
Net tangible asset backing per ordinary share (cents)	0.07 cent	0.09 cent

A Review of operations is included in the Directors' Report of the attached Half Year Report of Tyrian Diagnostics Limited and its controlled entities.

This Appendix 4D is based on Financial Reports which have been subject to review.

Tyrian Diagnostics Limited
Interim Financial Report – 31 December 2014
ACN 080 277 998

Contents

Directors' report	3
Auditor's independence declaration	5
Statement of comprehensive income	6
Statement of financial position	7
Statement of changes in equity	8
Statement of cash flows	9
Notes to the financial statements	10
Directors' declaration	12
Independent auditor's review report to the members	13

The interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by Tyrian Diagnostics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Tyrian Diagnostics Limited
Directors' report
For the half-year ended 31 December 2014

The Directors of Tyrian Diagnostics Limited (the "Company") present their report on the Company for the half-year to 31 December 2014.

Directors

The following persons were directors of Tyrian Diagnostics Limited during the whole of the half-year to 31 December 2014 and up to the date of this report:

Roger Amos (Chairman)
Caroline Popper
Marilyn Sleigh

Principal activities

During the half-year the principal continuing activities of the company consisted of:

- a) Business development activities related to the commercialisation of the company's TB intellectual property including engaging with suitable partners to licence the company's patented molecular TB biomarker for development and commercialisation of tests to diagnose active TB;
- b) Seeking and engaging with partners to further develop the company's proprietary DiagnostIQ platform for diagnostic testing;
- c) During the half-year the company has been actively involved in assessing a number of opportunities to maximise the value of the company's assets for the benefit of shareholders.

Comments on the operations and the results of those operations are set out below.

REVIEW AND RESULTS OF OPERATIONS

Results

Revenue and Other Income from continuing operations to 31 December 2014 was \$27,816 (\$311,671 to 31 December 2013). The net loss after tax in the half-year to 31 December 2014 was \$162,656 (Profit \$108,541 to 31 December 2013).

Cash Used in Operations

Net cash outflows from operating activities increased from \$88,979 in the previous corresponding period to \$109,200 in the current half-year.

Operations Review

Strategic Opportunities

The company, working with its advisors, TC Corporate has been actively involved in identifying and assessing a number of corporate opportunities to maximise the value of the company's remaining assets for the benefit of shareholders.

Commercialising the TB Intellectual Property

Tyrian continues in its management of licences of its TB intellectual property for rapid protein and molecular diagnostic tests to companies developing new point-of-care diagnostic platforms with higher sensitivity of detection than current technologies.

Commercialising Tyrian's DiagnostIQ Technology

During 2012 an agreement was reached with Australian diagnostic company Agenix Limited for a licence to the use of DiagnostIQ for medical applications. Terms for the licence required payment to Tyrian of Agenix shares, valued at a total of \$500,000 at time of issue. Shares were issued to Tyrian in instalments up to June 2014 and the last of these shares were sold in the current half-year.

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

There have been no significant changes in the state of affairs of the Company during the half-year ended 31 December 2014.

SIGNIFICANT EVENTS AFTER THE BALANCE DATE

No matter or circumstance has arisen since 31 December 2014 that has significantly affected, or may significantly affect:

- (a) the Company's operations in future financial years, or
- (b) the results of those operations in future financial years, or
- (c) the Company's state of affairs in future financial years.

LIKELY DEVELOPMENTS AND EXPECTED RESULTS

Any further information on likely developments in the operations of the Company and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the Company.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditors' independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 5.

This report is made in accordance with a resolution of the directors.



Roger Amos
Chairman

Sydney
20 February 2015



Auditor's Independence Declaration

As lead auditor for the review of Tyrian Diagnostics Limited for the half-year ended 31 December 2014, I declare that to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Tyrian Diagnostics Limited during the period.


Michelle Chiang
Partner
PricewaterhouseCoopers

Sydney
20 February 2015

PricewaterhouseCoopers, ABN 52 780 433 757

Darling Park Tower 2, 201 Sussex Street, GPO BOX 2650, SYDNEY NSW 1171

DX 77 Sydney, Australia

T +61 2 8266 0000, F +61 2 8266 9999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

Tyrian Diagnostics Limited
Statement of comprehensive income
For the half-year ended 31 December 2014

	Notes	Half-year 2014 \$	2013 \$
Revenue from continuing operations		27,816	311,671
Corporate & administration expenses		(168,147)	(185,543)
Patent costs		(22,325)	(17,587)
Profit/(Loss) before income tax		(162,656)	108,541
Income tax expense		-	-
Profit/(Loss) from continuing operations		(162,656)	108,541
Profit/(Loss) for the half year attributable to members of Tyrian Diagnostics Limited		(162,656)	108,541
Total comprehensive profit/(loss) attributable to members of Tyrian Diagnostics Limited		(162,656)	108,541

Earnings per share from continuing operations attributable to the ordinary equity holders of the company:	Cents	Cents
Basic earnings per share	0.0	0.0
Diluted earnings per share	0.0	0.0
Earnings per share attributable to the ordinary equity holders of the company:	Cents	Cents
Basic earnings per share	0.0	0.0
Diluted earnings per share	0.0	0.0

The above Statement of comprehensive income should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of financial position
31 December 2014

		31 December 2014 \$	30 June 2014 \$
	Notes		
ASSETS			
Current assets			
Cash and cash equivalents		706,462	815,662
Financial assets at fair value through profit or loss	4	-	53,514
Other assets		31,951	29,029
Total current assets		<u>738,413</u>	<u>898,205</u>
Total assets		<u>738,413</u>	<u>898,205</u>
LIABILITIES			
Current liabilities			
Trade and other payables		36,986	34,122
Total current liabilities		<u>36,986</u>	<u>34,122</u>
Total liabilities		<u>36,986</u>	<u>34,122</u>
Net assets		<u>701,427</u>	<u>864,083</u>
EQUITY			
Contributed equity	3	123,625,663	123,625,663
Reserves		3,798,735	3,798,735
Accumulated losses		<u>(126,722,971)</u>	<u>(126,560,315)</u>
Parent entity interest		<u>701,427</u>	<u>864,083</u>

The above Statement of financial position should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of changes in equity
For the half-year ended 31 December 2014

	Attributable to owners of Tyrian Diagnostics Limited			
	Contributed Equity \$	Reserves \$	Retained Earnings \$	Total Equity \$
Balance at 1 July 2013	123,625,663	3,798,735	(126,640,024)	784,374
Profit for the half-year	-	-	108,541	108,541
Total comprehensive profit for the half-year	-	-	108,541	108,541
Balance at 31 December 2013	123,625,663	3,798,735	(126,531,483)	892,915
Balance at 1 July 2014	123,625,663	3,798,735	(126,560,315)	864,083
Loss for the half-year	-	-	(162,656)	(162,656)
Total comprehensive loss for the half-year	-	-	(162,656)	(162,656)
Balance at 31 December 2014	123,625,663	3,798,735	(126,722,971)	701,427

The above Statement of changes in equity should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of cash flows
For the half-year ended 31 December 2014

	Notes	Half-year 2014 \$	2013 \$
Cash flows from operating activities			
Receipts from customers (inclusive of goods and services tax)		82,872	148,028
Payments to suppliers and employees (inclusive of goods and services tax)		(201,722)	(248,765)
		(118,850)	(100,737)
Interest received		9,650	11,758
Net cash outflow from operating activities		(109,200)	(88,979)
Net increase (decrease) in cash and cash equivalents		(109,200)	(88,979)
Cash and cash equivalents at the beginning of the half-year		815,662	915,335
Cash and cash equivalents at end of the half-year		706,462	826,356

The above Statement of cash flows should be read in conjunction with the accompanying notes.

1 Summary of significant accounting policies

These general purpose financial statements for the interim half year reporting period ended 31 December 2014 have been prepared in accordance with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by Tyrian Diagnostics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and the corresponding interim reporting period.

(a) Basis of preparation of half-year financial report

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

Critical accounting estimates

The preparation of financial statements in conformity with AIFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities.

Historical cost convention

These financial statements have been prepared under the historical cost convention, as modified by certain financial assets and liabilities (including derivative instruments) at fair value through profit or loss.

Going Concern

During the period ended 31 December 2014 the company incurred a loss from continuing operations before tax of \$162,656 (2013: Profit \$108,541) and net cash outflows from operating activities of \$109,200 (2013: \$88,979).

Having regard to cash-flow forecasts prepared by the company, the directors believe the company will be able to pay its debts as and when they become due and payable and will continue as a going concern for a period of at least 12 months from the date of the Directors' Report. The financial statements have therefore been prepared on a going concern basis.

2 Segment reporting

AASB 8 *Operating Segments* requires a 'management approach' under which segment information is presented on the same basis as that used for internal reporting to key decision makers to evaluate segment performance and decide how to allocate resources to segments. This has resulted in the company being considered as one reportable segment.

Operating segments are reported in a manner that is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision-maker has been identified as the Board of directors.

Tyrian Diagnostics Limited
Notes to the financial statements continued
31 December 2014

3 Contributed equity

Movements in ordinary share capital:

Details	Number of shares	\$
Balance at 1 January 2014	1,022,027,092	123,625,663
Balance as at 30 June 2014	1,022,027,092	123,625,663
Balance as at 31 December 2014	1,022,027,092	123,625,663

4 Financial assets at fair value through profit or loss

	2014	2013
	\$	\$
Shares in Agenix Limited	-	53,514
	-	53,514

Pursuant to the licence agreement with Agenix Limited, Tyrian Diagnostics Limited held no shares in the listed company at 31 December 2014 (30 June 2014 - 4,864,912 shares at 1.1 cents per share).

5 Events occurring after the balance sheet date

The company is not aware of any matters or circumstances which are not otherwise dealt with in the financial statements that have significantly, or may significantly, affect the operations of the company, the results of its operations or the state of the company in subsequent years.

Tyrian Diagnostics Limited
Directors' Declaration
31 December 2014

In the directors' opinion:

- a. the financial statements and notes set out on pages 3 to 11 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
 - (ii) giving a true and fair view of the company's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
- b. there are reasonable grounds to believe that Tyrian Diagnostics Limited will be able to pay its debts as and when they become due and payable, as discussed in Note 1 to the financial statements.

This declaration is made in accordance with a resolution of the directors.



Roger Amos
Chairman

Sydney
20 February 2015



Independent auditor's review report to the members of Tyrian Diagnostics Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Tyrian Diagnostics Limited, which comprises the statement of financial position as at 31 December 2014 and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, selected explanatory notes and the directors' declaration for Tyrian Diagnostics Limited (the company).

Directors' responsibility for the half-year financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the company's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Tyrian Diagnostics Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

PricewaterhouseCoopers, ABN 52 780 433 757

Darling Park Tower 2, 201 Sussex Street, GPO BOX 2650, SYDNEY NSW 1171

DX 77 Sydney, Australia

T +61 2 8266 0000, F +61 2 8266 9999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.




**Independent auditor's review report to the members of
Tyrian Diagnostics Limited (continued)**

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Tyrian Diagnostics Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the company's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.


PricewaterhouseCoopers


Michelle Chiang
Partner

Sydney
20 February 2015